

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NEPTUNE GENERICS, LLC,
Petitioner,

v.

CORCEPT THERAPEUTICS, INC.,
Patent Owner.

Case IPR2018-01494
U.S. Patent No. 8,921,348

PATENT OWNER'S RESPONSE

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. BACKGROUND	6
A. Mifepristone and Its Unusual Pharmacologic Properties.....	6
B. The '348 Patent Invention	12
C. Neptune's Validity Challenge	14
III. CLAIM CONSTRUCTION	17
IV. PETITIONER'S PRIOR ART REFERENCES	18
A. Belanoff & Murphy Mental Disorder References.....	18
1. Belanoff '953	19
2. Belanoff '848	21
3. Belanoff 2002.....	23
4. Chu & Belanoff.....	25
5. Murphy.....	26
B. Sitruk-Ware Contraceptive Reference	27
V. PETITIONER'S GROUNDS FOR UNPATENTABILITY	30
VI. PETITIONER HAS FAILED TO CARRY ITS BURDEN OF PROVING, BY A PREPONDERANCE OF THE EVIDENCE, THAT THE '348 PATENT CLAIMS WOULD HAVE BEEN OBVIOUS	31
A. Ground 1	31
1. Belanoff '848 Would Not Have Motivated a POSA to Measure and Monitor Mifepristone Serum Levels In Evaluating Efficacy.....	32

2.	Belanoff '848 Would Not Have Motivated a POSA to Target the Key 1300 ng/mL Level, and a POSA Would Have Had No Reasonable Expectation of Success in Achieving the Key 1300 ng/mL Level Based on the Belanoff '848 Dosages.....	35
3.	Based on Belanoff '848 and Knowledge in the Art, a POSA Would Have Been Surprised to Learn that a Threshold Blood Level of 1300 ng/mL Could Be Used to Adjust Dosing	36
B.	Ground 2.....	38
1.	Nothing in the References Overcomes the Teaching Away in the Field From Assessing Efficacy and Adjusting Dose Based on Measuring Drug Serum Levels	40
2.	Sitruk-Ware Does Not Establish a Correlation Between Mifepristone Dose and Serum Level of 1300 ng/mL	42
a)	C_{max} is Not a Mean Serum Level	42
b)	Petitioner's Expert Admitted He Failed to Disclose that Sitruk-Ware Reports Data from the Inaccurate RIA Method.....	44
c)	Sitruk-Ware's Antiprogestin, Single-Dose, C_{max} , Disclosure Would Not Motivate a POSA to Arrive at the Key 1300 ng/mL Level for Efficacy.....	46
3.	The Federal Circuit's Decision in <i>Cyclobenzaprine</i> Establishes that the Lack of Disclosure of a PK-PD Relationship in Petitioner's Cited Prior Art Renders the '348 Patent Invention Non-Obvious	50
4.	A POSA Would Have Had No Motivation to Combine The Contraceptive Reference (Sitruk-Ware) With The Mental Disorder References (Belanoff & Murphy).....	53
C.	Ground 3.....	55
D.	Ground 4.....	55

E. Ground 5.....56

F. Ground 6.....57

G. Dr. Heikinheimo's Failure Confirms that a POSA Would Have Had No Reasonable Expectation of Success.....57

H. The Patent Office Already Determined That the '348 Invention Was Non-Obvious Because the Correlation Between the Serum Level and Efficacy Was Unknown.....59

VII. CONCLUSION.....61

TABLE OF AUTHORITIES**Page(s)****CASES**

<i>Cuozzo Speed Techs., LLC v. Lee</i> , 136 S. Ct. 2131 (2016).....	17
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012)	51, 52, 53
<i>Endo Pharms. Inc. v. Actavis LLC</i> , No. 2018-1052, 2019 WL 1967605 (Fed. Cir. May 3, 2019).....	38, 50
<i>Leo Pharm. Prods., Ltd. v. Rea</i> , 726 F.3d 1346 (Fed. Cir. 2013)	58, 59
<i>Valeo N. Am., Inc. v. Schaeffler Techs. AG & Co. KG</i> , No. IPR2016-00502, 2017 WL 2664384 (P.T.A.B. June 20, 2017)	38, 50

REGULATIONS

37 C.F.R. § 42.100(b)	17
-----------------------------	----

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.